Literature DB >> 23652215

Clinical impact of early brain atrophy in clinically isolated syndromes.

F Pérez-Miralles1, J Sastre-Garriga, M Tintoré, G Arrambide, C Nos, H Perkal, J Río, M C Edo, A Horga, J Castilló, C Auger, E Huerga, A Rovira, X Montalban.   

Abstract

BACKGROUND: The impact of global and tissue-specific brain atrophy on conversion to multiple sclerosis (MS) after a clinically isolated syndrome (CIS) is not fully gauged.
OBJECTIVES: We aimed to determine the magnitude and clinical relevance of brain volume dynamics in the first year after a CIS.
METHODS: We assessed 176 patients with CIS within 3 months of onset, clinically and by conventional magnetic resonance imaging (MRI) scans, at baseline and 1 year after clinical onset. We determined the percentage of brain volume change (PBVC) and the brain parenchymal (BPF), grey matter (GMF) and white matter (WMF) fractions.
RESULTS: The mean follow-up time was 53 months (SD = 16.8): 76 patients (43%) experienced a second attack, 32 (18%) fulfilled MRI-only 2005 McDonald criteria and 68 (39%) remained as CIS. Statistically significant decreases in the volume measures tested were observed in patients with a second attack, for BPF and PBVC; in both MS groups for GMF; whereas in all groups, the WMF was unchanged. Patients with a second attack had larger PBVC decreases (- 0.65% versus + 0.059%; p < 0.001). PBVC decreases below - 0.817% independently predicted shorter times to a second attack.
CONCLUSIONS: Global brain and grey matter volume loss occurred within the first year after a CIS; brain volume loss predicted conversion to MS.

Entities:  

Keywords:  Brain atrophy; brain volume; clinically isolated syndrome; disability; grey matter; magnetic resonance imaging; multiple sclerosis

Mesh:

Substances:

Year:  2013        PMID: 23652215     DOI: 10.1177/1352458513488231

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  35 in total

Review 1.  Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients.

Authors:  Mike P Wattjes; Àlex Rovira; David Miller; Tarek A Yousry; Maria P Sormani; Maria P de Stefano; Mar Tintoré; Cristina Auger; Carmen Tur; Massimo Filippi; Maria A Rocca; Franz Fazekas; Ludwig Kappos; Chris Polman
Journal:  Nat Rev Neurol       Date:  2015-09-15       Impact factor: 42.937

Review 2.  Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy.

Authors:  Angela Vidal-Jordana; Jaume Sastre-Garriga; Alex Rovira; Xavier Montalban
Journal:  J Neurol       Date:  2015-06-05       Impact factor: 4.849

Review 3.  Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process.

Authors:  Àlex Rovira; Mike P Wattjes; Mar Tintoré; Carmen Tur; Tarek A Yousry; Maria P Sormani; Nicola De Stefano; Massimo Filippi; Cristina Auger; Maria A Rocca; Frederik Barkhof; Franz Fazekas; Ludwig Kappos; Chris Polman; David Miller; Xavier Montalban
Journal:  Nat Rev Neurol       Date:  2015-07-07       Impact factor: 42.937

4.  MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry.

Authors:  Kerstin Bendfeldt; Bernd Taschler; Laura Gaetano; Philip Madoerin; Pascal Kuster; Nicole Mueller-Lenke; Michael Amann; Hugo Vrenken; Viktor Wottschel; Frederik Barkhof; Stefan Borgwardt; Stefan Klöppel; Eva-Maria Wicklein; Ludwig Kappos; Gilles Edan; Mark S Freedman; Xavier Montalbán; Hans-Peter Hartung; Christoph Pohl; Rupert Sandbrink; Till Sprenger; Ernst-Wilhelm Radue; Jens Wuerfel; Thomas E Nichols
Journal:  Brain Imaging Behav       Date:  2019-10       Impact factor: 3.978

Review 5.  Clinical relevance of brain volume measures in multiple sclerosis.

Authors:  Nicola De Stefano; Laura Airas; Nikolaos Grigoriadis; Heinrich P Mattle; Jonathan O'Riordan; Celia Oreja-Guevara; Finn Sellebjerg; Bruno Stankoff; Agata Walczak; Heinz Wiendl; Bernd C Kieseier
Journal:  CNS Drugs       Date:  2014-02       Impact factor: 5.749

6.  PLXNA3 Variant rs5945430 is Associated with Severe Clinical Course in Male Multiple Sclerosis Patients.

Authors:  Moaz Qureshi; Mohamed Hatem; Raed Alroughani; Sindhu P Jacob; Rabeah Abbas Al-Temaimi
Journal:  Neuromolecular Med       Date:  2017-05-23       Impact factor: 3.843

7.  Measurement of Cortical Thickness and Volume of Subcortical Structures in Multiple Sclerosis: Agreement between 2D Spin-Echo and 3D MPRAGE T1-Weighted Images.

Authors:  A Vidal-Jordana; D Pareto; J Sastre-Garriga; C Auger; E Ciampi; X Montalban; A Rovira
Journal:  AJNR Am J Neuroradiol       Date:  2016-11-24       Impact factor: 3.825

8.  Adding brain volume measures into response criteria in multiple sclerosis: the Río-4 score.

Authors:  Francisco Carlos Pérez-Miralles; Jordi Río; Deborah Pareto; Àngela Vidal-Jordana; Cristina Auger; Georgina Arrambide; Joaquín Castilló; Mar Tintoré; Àlex Rovira; Xavier Montalban; Jaume Sastre-Garriga
Journal:  Neuroradiology       Date:  2020-11-25       Impact factor: 2.804

9.  Regional hippocampal vulnerability in early multiple sclerosis: Dynamic pathological spreading from dentate gyrus to CA1.

Authors:  Vincent Planche; Ismail Koubiyr; José E Romero; José V Manjon; Pierrick Coupé; Mathilde Deloire; Vincent Dousset; Bruno Brochet; Aurélie Ruet; Thomas Tourdias
Journal:  Hum Brain Mapp       Date:  2018-01-13       Impact factor: 5.038

Review 10.  Paediatric clinically isolated syndromes: report of seven cases, differential diagnosis and literature review.

Authors:  Chiara Trabatti; Thomas Foiadelli; Maria Valentina Spartà; Chiara Gagliardone; Berardo Rinaldi; Maria Delmonte; Alessandro Lozza; Salvatore Savasta
Journal:  Childs Nerv Syst       Date:  2015-11-19       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.